GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Operating Margin %

MindBio Therapeutics (XCNQ:MBIO) Operating Margin % : 7.91% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. MindBio Therapeutics's Operating Income for the three months ended in Dec. 2023 was C$0.01 Mil. MindBio Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.18 Mil. Therefore, MindBio Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 was 7.91%.

The historical rank and industry rank for MindBio Therapeutics's Operating Margin % or its related term are showing as below:

XCNQ:MBIO' s Operating Margin % Range Over the Past 10 Years
Min: -1531.64   Med: 0   Max: 0
Current: -1531.64


XCNQ:MBIO's Operating Margin % is ranked worse than
78.08% of 1031 companies
in the Biotechnology industry
Industry Median: -168.39 vs XCNQ:MBIO: -1531.64

MindBio Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

MindBio Therapeutics's Operating Income for the three months ended in Dec. 2023 was C$0.01 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was C$-2.71 Mil.


MindBio Therapeutics Operating Margin % Historical Data

The historical data trend for MindBio Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Operating Margin % Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23
Operating Margin %
- - -

MindBio Therapeutics Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Margin % Get a 7-Day Free Trial Premium Member Only - - - - 7.91

Competitive Comparison of MindBio Therapeutics's Operating Margin %

For the Biotechnology subindustry, MindBio Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MindBio Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Operating Margin % falls into.



MindBio Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

MindBio Therapeutics's Operating Margin % for the fiscal year that ended in Jun. 2023 is calculated as

Operating Margin %=Operating Income (A: Jun. 2023 ) / Revenue (A: Jun. 2023 )
=-2.822 / 0
= %

MindBio Therapeutics's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=0.014 / 0.177
=7.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MindBio Therapeutics  (XCNQ:MBIO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


MindBio Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics (XCNQ:MBIO) Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.

MindBio Therapeutics (XCNQ:MBIO) Headlines

From GuruFocus